Max Jacobs's questions to InMed Pharmaceuticals (INM) leadership • Q4 2021
Question
Max Jacobs of Edison Investment Research inquired about the product launch timeline for new cannabinoids from BayMedica, the customer profile for its current CBC product, and the expected timing for an IND filing for the INM-088 glaucoma treatment.
Answer
President and CEO Eric Adams explained that guidance on new cannabinoid launches would follow the acquisition's close, but launches are expected in the coming quarters. He described the current CBC customer base as B2B, including wholesale distributors and product formulators. For INM-088, he confirmed the target for an IND filing is the second half of calendar 2022, pending toxicology studies and FDA meetings.